skip to primary navigationskip to content
 

Immunotherapy - Cancer cure?

last modified Feb 17, 2016 03:31 PM
The researchers genetically modified the t-cells to engineer a new targeting mechanism - chimeric antigen receptors - to target acute lymphoblastic leukaemia.

The early stage trials in today’s reports involved patients with different types of blood cancer – including acute lymphoblastic leukaemiachronic lymphocyte leukaemia and non-Hodgkin lymphoma. While these are often very treatable forms of cancer, the patients on these trials had diseases that had become resistant to all other treatments.

Many media reports focused on the patients with acute lymphoblastic leukaemia, more than nine in 10 of whom are reported to have entered remission following the immune cell therapy.

The researchers are also reported to have seen similarly impressive responses in around half of patients with the other blood cancers too.

These are indeed truly impressive results.

But these responses – where patients see their symptoms disappear – don’t necessarily mean a patient has been cured. And without a scientific paper to back up the reports, we don’t yet have the full details on these responses rates – notably exactly how they were measured.

 

More on this story can be found at the CRUK site here.

Upcoming events

Emerging Viruses of Zoonotic and Veterinary Importance

Jul 24, 2017

Churchill College, Cambridge

Antibody Technologies and Therapeutics Conference

Sep 10, 2017

Monash University Conference Centre Prato , Italy

Exploring Human Host-Microbiome Interactions in Health and Disease

Sep 13, 2017

Wellcome Conference Centre, Hinxton

Upcoming events

The new Capella building- CITIID

See the home of CITIID being built in this fantastic time-lapse video. From basement to water tight in 17 months. The Capella building will be finished in 2018.

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more